Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine

Vaccine

Volumn 26, Issue 38, 2008, Pages 4918-4926

  Ramírez, Belinda Sánchez ^a   Alpízar, Yeranddy Aguiar ^a   Fernández, Diana Rosa Hernández ^a   Hidalgo, Greta Garrido ^a   Capote, Ailem Rabasa ^a   Rodríguez, Rolando Pérez ^a   Fernández, Luis Enrique ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer; Polyclonal antibodies; Vaccine

Indexed keywords

ADJUVANT; CANCER VACCINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEOLIPOSOME;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; APOPTOSIS; CACO-2 CELLS; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEIN BINDING; PROTEOLIPIDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 50249128651     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.018     Document Type: Article

References (51)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Hendler F.J., and Ozanne B.W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74 2 (1984) 647-651
3. Perez R., Pascual M., Macias A., and Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 4 3 (1984) 189-193
4. Gullick W.J., Marsden J.J., Whittle N., Ward B., Bobrow L., and Waterfield M.D. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res 46 1 (1986) 285-292
5. Lockhart C., and Berlin J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32 1 (2005) 52-60
6. Dassonville O., Formento J.L., Francoual M., Ramaioli A., Santini J., Schneider M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 10 (1993) 1873-1878
7. Zhau H.Y., Chang S.M., Chen B.Q., Wang Y., Zhang H., Kao C., et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 93 26 (1996) 15152-15157
8. Liu X.H., Wiley H.S., and Meikle A.W. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metab 77 6 (1993) 1472-1478
9. Neal D.E., Marsh C., Bennett M.K., Abel P.D., Hall R.R., Sainsbury J.R., et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1 8425 (1985) 366-368
10. Tan X., Egami H., Ishikawa S., Nakagawa M., Ishiko T., Kamohara H., et al. Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. Int J Oncol 25 5 (2004) 1303-1309
11. Nicholson R.I., Gee J.M., and Harper M.E. EGFR and cancer prognosis. Eur J Cancer 37 Suppl. 4 (2001) S9-S15
12. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 78 (2000) 31-101
13. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 5967 (1984) 418-425
14. Normanno N., Bianco C., Strizzi L., Mancino M., Maiello M.R., De Luca A., et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6 3 (2005) 243-257
15. Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257 5524 (1975) 325-327
16. Salomon D.S., Kim N., Saeki T., and Ciardiello F. Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells 2 12 (1990) 389-397
17. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11 2 (2003) 495-505
18. Boerner J.L., Danielsen A., and Maihle N.J. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res 284 1 (2003) 111-121
19. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
20. Montgomery R.B., Makary E., Schiffman K., Goodell V., and Disis M.L. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65 2 (2005) 650-656
21. Salomon D., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 3 (1995) 183-232
22. Systems-ImClone. Erbitux (Cetuximab). US prescribing information (2004), ImClone System, Princeton, NJ
23. Crombet T., Osorio M., Cruz T., Roca C., del Castillo R., Mon R., et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22 9 (2004) 1646-1654
24. Lu Y., Wei Y.Q., Tian L., Zhao X., Yang L., Hu B., et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 170 6 (2003) 3162-3170
25. Hu B., Wei Y., Tian L., Zhao X., Lu Y., Wu Y., et al. Active antitumor immunity elicited by vaccine based on recombinant form of epidermal growth factor receptor. J Immunother 28 3 (2005) 236-244
26. Ramirez B.S., Pestana E.S., Hidalgo G.G., Garcia T.H., Rodriguez R.P., Ullrich A., et al. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer 119 9 (2006) 2190-2199
27. Mesa C., de Leon J., and Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 24 14 (2006) 2692-2699
28. Mesa C., De Leon J., Rigley K., and Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22 23-24 (2004) 3045-3052
29. Carney D.N., Gazdar A.F., Bepler G., Guccion J.G., Marangos P.J., Moody T.W., et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45 6 (1985) 2913-2923
30. Bergh J., Nilsson K., Ekman R., and Giovanella B. Establishment and characterization of cell lines from human small cell and large cell carcinomas of the lung. Acta Pathol Microbiol Immunol Scand A 93 3 (1985) 133-147
31. Estevez F., Carr A., Solorzano L., Valiente O., Mesa C., Barroso O., et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18 1-2 (1999) 190-197
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 1-2 (1983) 55-63
33. Brezicka T., and Einbeigi Z. Supra-additive cytotoxic effects of a combination of cytostatic drugs and antibody-induced complement activation on tumor cells in vitro. Tumour Biol 22 2 (2001) 97-103
34. Forsthuber T., Yip H.C., and Lehmann P.V. Induction of TH1 and TH2 immunity in neonatal mice. Science 271 5256 (1996) 1728-1730
35. Suarez Pestana E., Greiser U., Sanchez B., Fernandez L.E., Lage A., Perez R., et al. Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 75 2 (1997) 213-220
36. Wrann M.M., and Fox C.F. Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem 254 17 (1979) 8083-8086
37. Wang H., Yu J., Yang G.R., Song X.R., Sun X.R., Zhao S.Q., et al. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035. Chin Med J 120 11 (2007) 960-964
38. Li S., Schmitz K.R., Jeffrey P.D., Wiltzius J.J., Kussie P., and Ferguson K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7 4 (2005) 301-311
39. Jo M., Stolz D.B., Esplen J.E., Dorko K., Michalopoulos G.K., and Strom S.C. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275 12 (2000) 8806-8811
40. Holbro T., and Hynes N.E. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44 (2004) 195-217
41. Moosmann N., and Heinemann V. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Rev Anticancer Ther 8 3 (2008) 319-329
42. Ramos T.C., Figueredo J., Catala M., Gonzalez S., Selva J.C., Cruz T.M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5 4 (2006) 375-379
43. Garrido G., Lorenzano P., Sanchez B., Beausoleil I., Alonso D.F., Perez R., et al. T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother 56 11 (2007) 1701-1710
44. Guthmann M.D., Bitton R.J., Carnero A.J., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 27 6 (2004) 442-451
45. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110 6 (2002) 763-773
46. Wu X., Fan Z., Masui H., Rosen N., and Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95 4 (1995) 1897-1905
47. Tian X.X., Lam P.Y., Chen J., Pang J.C., To S.S., Di-Tomaso E., et al. Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation. Neuropathol Appl Neurobiol 24 5 (1998) 389-396
48. Rodeck U., Jost M., Kari C., Shih D.T., Lavker R.M., Ewert D.L., et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110 Part 2 (1997) 113-121
49. Restifo N. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptative immunity. Curr Opin Immunol 12 (2000) 597-603
50. Fen H., Zeng Y., Graner M.W., and Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 100 (2002) 4108-4115
51. Shi Y., Evans J.E., and Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003) 516-521